PBC is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment plans for and management of PBC require individualized development, typically including drug therapy, rehabilitation interventions, regular follow-up management, etc. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of primary biliary cholera PBC. The platform serves China International Medical Service System, a team of authoritative experts at home and abroad in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.